Insight 6 October 2026 · updated 6 October 2026

McDonald's and GLP-1: A Protein Offering Boost in the Works

McDonald's is exploring adjustable portions and higher protein content in response to GLP-1 medications. What do nutrition guidelines say, and what opportunities does this create for food manufacturers?

Nicolas Rousseau — Nutritionist (UCLouvain)

At a glance - As GLP-1 treatments gain ground, McDonald’s is exploring, in the United States, more adjustable portions and an offering where protein plays a bigger role. This commercial shift is not, however, enough on its own to make a meal suitable for people on treatment: overall composition, tolerance and individual needs remain the determining factors. For food industry players, the signal is clear: nutritional value could matter more, even in smaller portions.

Protein is becoming a positioning argument at McDonald’s: on 23 September 2026, at its investor day in Chicago, the chain unveiled product directions (bowls, grilled chicken, egg bites) to cater to customers on GLP-1 treatments, according to Axios and Yahoo Finance [1][2]. McDonald’s claims that 84% of households with a GLP-1 user already visit the chain [1]. For ingredient suppliers, the useful signal is not the menu itself. It is the shift in value proposition towards less volume and greater nutritional density.

The first thing to clarify before any portfolio review is that what was announced is neither a launch nor a budget. Chris Kempczinski stated that not all the new products would appear on the menu by 1 January [1]. As for the $8.5 billion figure cited in the press, it relates to the broader McDonald’s > NEXT programme, running through 2036, not a bet on “slimming-down menus” [3]. Conflating the two skews the strategic trade-off.

The verdict: a density signal, not a volume order

What the investor day changes, right now, can be summed up in one sentence: a company serving tens of millions of meals a day is starting to treat protein as a selection benchmark, not just a recipe attribute. Since April 2026, McDonald’s has been displaying protein content for 17 products in its app and kiosks, and claims more than 30 items with 15g or more, according to Fortune [4].

For your product lines, the nuance is decisive. The chain is not promising to reformulate its recipes: it is making a nutrient more visible at the point of choice. In other words, communication innovation is here moving faster than product innovation [4]. McDonald’s protein-rich foods are primarily designed to retain existing customers whose appetite is changing under GLP-1, molecules that reduce food intake.

The targeted market goes beyond patients. Based on its own research, McDonald’s estimates that 60 million Americans are seeking to increase their protein intake [1]. This convergence between medication users and mainstream “proteinmaxxing” outlines your real target: ingredients that deliver on the promise in compact formats.

Why is this signal emerging now for your portfolios?

GLP-1 treatments used against obesity alter appetite and can sharply reduce intake [5][6]. When consumed quantities fall, the challenge shifts: it is no longer about eating less, but about maintaining a sufficiently nutritious diet, preventing deficiencies and preserving muscle mass. This is exactly the territory of functional ingredients.

A joint advisory from four learned societies, published in 2025 in Obesity, places adequate protein intake among the priorities [6]. It cites targets of 1.2 to 1.6g of protein per kilogram per day during active weight loss, combined with resistance training [6].

Beware of the commercial shortcut. The authors highlight uncertainty around the reference weight (actual, adjusted, or lean body mass): these values do not automatically translate into a number of burgers [6]. The same document recommends varied, minimally processed foods, and advises limiting most fast food [6]. In other words, the science does not endorse the chain: it describes a need that demand, in turn, is pushing towards your industrial clients.

The demonstration: what “small and protein-rich” demands of your ingredients

Small and protein-rich is not enough. A crispy chicken bowl does not have the same profile as a grilled chicken bowl: frying, sauces, cheese and toppings change the final meal. Physician Jesse Pines, in his analysis published on 5 October 2026 on Forbes, points out that an approach focused solely on protein and portions ignores fat content and the digestive tolerance of certain patients [7].

For your R&D, this shifts optimisation away from a single metric towards the complete recipe. Here are the parameters that the “GLP-1 friendly” case makes more demanding than the stated protein content alone.

Criterion	“More grams” logic	“Density in less volume” logic
Objective	Maximise stated protein content	Maximise value per reduced portion
Format	Standard portion	Adjustable, compact portion
Sensory quality	Often sacrificed (texture, bitterness)	Taste and texture to be preserved
Fat / sauces	Out of scope	Assessed within the complete recipe
Digestive tolerance	Not documented	To be distinguished from composition data
Claimed evidence	Composition alone	Composition + tolerance + real-world use

The term “GLP-1 friendly” should be interpreted with caution. A marketing position demonstrates neither better tolerance nor clinical benefit [5][6][7]. A protein badge on a kiosk screen does not replace the nutritional guidance recommended by learned societies.

The obstacles, and how your teams can overcome them

The first obstacle is the confusion between trend and validation. Current announcements measure neither impact on sales, nor patient satisfaction, nor the quality of their diet [1][2][3]. Betting a budget on a “GLP-1 market” built from a household figure with no published methodology exposes your marketing team to backlash.

Four pragmatic levers for your ingredient teams.

Work on protein density without compromising sensory quality: a compact portion remains a failure if taste or texture falls short.
Develop adjustable formats, allowing for a suitable quantity rather than enforcing a standard menu.
Evaluate the complete recipe, including sauces and toppings, rather than optimising a single metric.
Document the claimed benefit: separate composition data from evidence of tolerance or efficacy.

These are formulation suggestions, not experimental results, and nothing indicates that they are already the subject of projects at McDonald’s. They nonetheless frame the trade-off your R&D and procurement directors will encounter as soon as a food industry client wants their own “small protein-rich format”.

What McDonald’s protein shift redistributes for the industry

For protein ingredient suppliers, the McDonald’s case suggests a simple rule: less volume should not mean less nutritional interest. The positioning that links GLP-1 users with protein-seeking consumers outlines a multi-segment supply logic, without any claim of medical effect [1]. This is an opportunity for your isolates, texturising systems and fortification solutions, provided you aim for value per portion.

McDonald’s proteins are not, therefore, a scientific stamp of approval: they are a demand barometer. The real challenge on the ingredients side is making a controlled, legible and nutritious portion credible, documented beyond protein content alone. The question to ask at your next innovation committee: can your protein portfolio prove its value in a format half the size, or only display it?

References

FAQ

Is McDonald’s really launching a GLP-1 range in 2026?

No. On 23 September 2026, the chain presented product directions (bowls, grilled chicken, egg bites), not a launch. Its CEO stated that not all of these products would appear on the menu by 1 January, and nothing indicates imminent availability in Belgium or France [1].

Is the $8.5 billion dedicated to GLP-1 menus?

No. This figure relates to McDonald’s broader “Accelerating the Arches > NEXT” programme, intended to speed up franchisee investment in restaurant modernisation through 2036. Presenting it as a bet on slimming-down menus is misleading, according to CNBC [3].

What does the 84% households figure mean?

According to Skye Anderson, President of McDonald’s USA, 84% of households with a GLP-1 user visit the chain. The figure relates to households, not the proportion of patients who regularly eat at McDonald’s. The methodology and visit frequency are not detailed in the sources reviewed [1][2].

Is a smaller, higher-protein meal suitable for GLP-1 patients?

Not automatically. The 2025 joint advisory recommends 1.2 to 1.6 g of protein/kg/day combined with resistance training, but highlights uncertainty around the reference weight used. It advises varied, minimally processed foods and limiting most fast food [6].

What does the “GLP-1 friendly” label prove for a product?

Nothing from a clinical standpoint. It is a marketing position that demonstrates neither better digestive tolerance nor medical benefit. The full composition and the portion actually consumed must be examined, distinguishing composition data from tolerance evidence [5][6][7].

What is the concrete signal for ingredient suppliers?

Lower volume should not mean lower nutritional interest. The challenge is shifting towards protein density in compact formats, adjustable portions, and evaluating the complete recipe, including sauces and toppings, rather than the stated protein content alone [1][4].

How large is the real market beyond GLP-1 patients?

Based on its own research, McDonald’s estimates that 60 million Americans are actively seeking to increase their protein intake. This is an internal estimate with no published methodology in the sources reviewed [1].